The Legal Authority for States’ Stay-at-Home Orders | NEJM
Perspective from The New England Journal of Medicine — The Legal Authority for States’ Stay-at-Home Orders
Related Articles
For Weight Loss, Does It Matter What Time of Day You Eat?
Time-restricted eating (i.e., confining calorie intake to a limited period of each day) leads to weight loss in animals, possibly because calories are
Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
Symptoms such as angina, heart failure, or syncope generally are indications for valve replacement in patients with severe aortic stenosis (AS), but do
Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
Patients with atrial fibrillation (AF) are at risk for developing rapid ventricular response and cardioembolic stroke. Although therapies to prevent
Minimizing Gestational Weight Gain Appears to Be Safe for People with Obesity
A 2009 guideline from the Institute of Medicine (IOM; renamed National Academy of Medicine in 2015) guidelines recommend gestational weight gain of 5
New Terms to Describe the Steatotic Liver
Medical terminology evolves just as all languages do, with new terms replacing older ones as scientific understanding, clinical practice, or cultural
Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
High levels of non–HDL cholesterol are increasingly common in children and adolescents. However, the association of childhood dyslipidemia with adult
Innovative Pairing of Beta-Lactamase Inhibitors to Combat Multidrug-Resistant Gram-Negative Pathogens
Resistance to antimicrobials has multifactorial mechanisms, and the ability of pathogens to hydrolyze beta-lactam (BL) antibiotics through
Ceftobiprole Joins the Beta-Lactam Squad Against MRSA Infections
Compared with methicillin-susceptible Staphylococcus aureus infection, methicillin-resistant S. aureus (MRSA) infection has been associated with worse
A Final Chat with Our Clinician-Guides for AAN 2024
Dr. Ali Raja talks to Dr. Teshamae Monteith and Dr. Seemant Chaturvedi about the biggest takeaways from AAN 2024.
Sulbactam-Durlobactam for Treating Patients with
Management of carbapenem-resistant Acinetobacter baumannii (CRAB) is a priority in the antimicrobial drug pipeline. The beta-lactam–beta-lactamase